DR info

Clinical trials : 81 / Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116

Drugs and their primary sponsors and trial info

2387066
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom;
3400935113276
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom;
8699505952864
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom;
AIN457
   Novartis Farmacéutica, S.A.
      2010   -   EUCTR2009-013901-33-ES   Austria;France;Germany;Greece;Spain;
      2009   Phase 3   EUCTR2009-011237-27-ES   Austria;France;Germany;Greece;Hungary;Italy;Spain;
   Novartis Pharma Services AG
      2010   -   EUCTR2009-013901-33-GR   Austria;France;Germany;Greece;Spain;
      2010   -   EUCTR2009-013901-33-FR   Austria;France;Germany;Greece;Spain;
      2010   -   EUCTR2009-013901-33-DE   Austria;France;Germany;Greece;Spain;
      2009   -   EUCTR2009-013901-33-AT   Austria;France;Germany;Greece;Spain;
      2009   -   EUCTR2009-011237-27-DE   Austria;France;Germany;Greece;Hungary;Italy;Spain;
      2009   -   EUCTR2009-011237-27-AT   Austria;France;Germany;Greece;Hungary;Italy;Spain;
   Novartis Pharma Services Ag
      2009   -   EUCTR2009-011237-27-HU   Austria;France;Germany;Greece;Hungary;Italy;Spain;
      2009   -   EUCTR2009-011237-27-GR   Austria;France;Germany;Greece;Hungary;Italy;Spain;
      2009   -   EUCTR2009-011237-27-FR   Austria;France;Germany;Greece;Hungary;Italy;Spain;
   Novartis Pharmaceuticals
      2009   Phase 3   NCT00995709   Austria;Brazil;Egypt;France;Germany;Greece;Hong Kong;Hungary;India;Israel;Italy;Jordan;Korea, Republic of;Saudi Arabia;Singapore;Spain;Switzerland;Taiwan;Tunisia;Turkey;United States;
AMG 407
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002787-27-IT   France;Greece;Israel;Italy;Netherlands;Switzerland;
AMG-407
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002787-27-GR   France;Greece;Israel;Netherlands;Switzerland;
      -   Phase 3   EUCTR2019-002787-27-NL   France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2019-002787-27-FR   France;Israel;Netherlands;Switzerland;
AMG407
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002787-27-IT   France;Greece;Israel;Italy;Netherlands;Switzerland;
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002787-27-GR   France;Greece;Israel;Netherlands;Switzerland;
      -   Phase 3   EUCTR2019-002787-27-NL   France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2019-002787-27-FR   France;Israel;Netherlands;Switzerland;
Adalimumab
   AbbVie (prior sponsor, Abbott)
      2010   Phase 3   NCT01243671   Japan;
   State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University
      2020   Phase 4   ChiCTR1900027147   China;
   The First Affiliated Hospital of Chongqing Medical University
      2020   Phase 4   ChiCTR2000031637   China;
   The First Affiliated Hospital, College of Medicine, Zhejiang University
      2021   Phase 4   ChiCTR2100045463   China;
Allogeneic Stem Cell Transplant
   Northwestern University
      2003   Phase 1   NCT00278512   United States;
Alpha interferon
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom;
Anakinra
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2011   Phase 1/Phase 2   NCT01441076   United States;
Apremilast
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002787-27-IT   France;Greece;Israel;Italy;Netherlands;Switzerland;
   Amgen
      2021   Phase 3   NCT04528082   France;Greece;Israel;Italy;Spain;Switzerland;United Kingdom;
      2014   Phase 3   NCT02307513   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Lebanon;Turkey;United States;
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002787-27-GR   France;Greece;Israel;Netherlands;Switzerland;
      -   Phase 3   EUCTR2019-002787-27-NL   France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2019-002787-27-FR   France;Israel;Netherlands;Switzerland;
Apremilast (CC-10004)
   Amgen
      2009   Phase 2   NCT00866359   Turkey;United States;
Autologous Stem Cell Transplant
   Northwestern University
      2003   Phase 1   NCT00278512   United States;
Autologous Stem Cell Transplantation
   Tehran University of Medical Sciences
      2007   Phase 1   NCT00550498   Iran, Islamic Republic of;
BFGF
   Turkish Ophthalmology Society
      2011   -   NCT01720628   Turkey;
CC-10004
   Amgen Inc.
      2015   Phase 3   EUCTR2014-002108-25-DE   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
   Celgene Corporation
      2016   Phase 3   EUCTR2014-002108-25-GR   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
      2015   Phase 3   EUCTR2014-002108-25-IT   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
Canakinumab
   Novartis Pharmaceuticals
      2016   Phase 2   NCT02756650   Turkey;
Colchicine
   Ipekyolu Ilac Ltd. Sti
      2019   Phase 2   NCT03888846   Turkey;
   Tehran University of Medical Sciences
      2002   Phase 2   NCT00700297   Iran, Islamic Republic of;
Cyclophosphamide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2017-002264-41-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03371095   -
Cyclosporin A
   University Hospital Tuebingen
      2004   Phase 3   NCT00167583   Germany;
Cyclosporine
   The First Affiliated Hospital of Chongqing Medical University
      2020   Phase 4   ChiCTR2000031637   China;
   Yokohama City University Hospital
      2017   -   JPRN-UMIN000025451   Japan;
Cyclosporine Pill
   Peking Union Medical College Hospital
      2017   Phase 3   NCT03209219   China;
Cytotoxic Combination
   Tehran University of Medical Sciences
      2006   Phase 2   NCT00664599   Iran, Islamic Republic of;
Daclizumab
   National Eye Institute (NEI)
      1999   Phase 2   NCT00001865   United States;
Dextrose
   Tehran University of Medical Sciences
      2010   Phase 4   NCT01306955   Iran, Islamic Republic of;
Entecavir
   Saitama Medical University
      2016   -   JPRN-UMIN000020029   Japan;
Etanercept, Methotrexate, Prednisolone
   Tehran University of Medical Sciences
      2010   -   NCT00931957   Iran, Islamic Republic of;
Flucinolone acetonide
   Asan Medical Center
      2008   Phase 4   NCT00720928   Korea, Republic of;
GSK1070806
   Cambridge University Hospitals NHS Foundation Trust
      2018   Phase 2   NCT03522662   United Kingdom;
Gevokizumab
   Institut de Recherches Internationales Servier
      2013   Phase 3   EUCTR2012-001125-27-PT   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
      2013   Phase 3   EUCTR2012-001125-27-GB   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
      2012   Phase 3   NCT01965145   Korea, Republic of;United Kingdom;
      2012   -   EUCTR2012-001125-27-GR   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
      2012   -   EUCTR2012-001125-27-DE   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
   Laboratorios Servier S.L.
      2012   -   EUCTR2012-001125-27-ES   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
   XOMA (US) LLC
      2014   Phase 3   NCT02258867   United States;
Golimumab (GOL)
   Wenjie Zheng
      2020   Phase 2   NCT04218565   China;
HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy;
Hemay005
   Tianjin Hemay Pharmaceutical Co.,Ltd
      2020   Phase 2   NCT04609397   China;
Hydroxychloroquine
   Assiut University
      2018   -   NCT04022421   Egypt;
INFLECTRA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy;
Ilaris
   University Hospital of Tübingen
      2011   -   EUCTR2010-024152-29-DE   Germany;
Infliximab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2017-002264-41-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03371095   -
   Janssen Korea, Ltd., Korea
      2015   Phase 3   NCT02505568   Korea, Republic of;
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom;
   Yokohama City University Hospital
      2017   -   JPRN-UMIN000025451   Japan;
Interferon alpha-2a
   The First Affiliated Hospital of Chongqing Medical University
      2020   Phase 4   ChiCTR2000031637   China;
Interferon-alpha2a
   University Hospital Tuebingen
      2004   Phase 3   NCT00167583   Germany;
Intravitreal Infliximab
   Cairo University
      2013   Phase 1/Phase 2   NCT02620618   -
J1081
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom;
Low-dose IL-2
   Peking University People's Hospital
      2019   Phase 2   NCT04065672   China;
MEDROL - 4 MG COMPRESSE 30 COMPRESSE
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy;
METILPREDNISOLONE SODIO SUCCINATO
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy;
Methylorednisolone
   Tehran University of Medical Sciences
      2010   Phase 4   NCT01306955   Iran, Islamic Republic of;
OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002787-27-IT   France;Greece;Israel;Italy;Netherlands;Switzerland;
Otezla
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002787-27-GR   France;Greece;Israel;Netherlands;Switzerland;
      2015   Phase 3   EUCTR2014-002108-25-DE   France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
      -   Phase 3   EUCTR2019-002787-27-NL   France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2019-002787-27-FR   France;Israel;Netherlands;Switzerland;
Pentoxifylline
   Ipekyolu Ilac Ltd. Sti
      2019   Phase 2   NCT03888846   Turkey;
Prednisolone
   Castle Study Group
      2013   -   JPRN-UMIN000012469   Japan;
Remicade
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2017-002264-41-FR   France;
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom;
RhumAb to Il-17A (IgG1-k-class)
   Novartis Pharma Services Ag
      2009   -   EUCTR2009-011237-27-FR   Austria;France;Germany;Greece;Hungary;Italy;Spain;
Rituximab
   Tehran University of Medical Sciences
      2006   Phase 2   NCT00664599   Iran, Islamic Republic of;
Roferon-A,
   The University of Liverpool
      2016   Phase 3   EUCTR2014-005390-36-GB   United Kingdom;
Rosuvastatin calcium
   University of Alexandria
      2010   -   NCT04328064   -
S78989
   INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
      2012   -   EUCTR2012-001125-27-IT   Brazil;China;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
   Institut de Recherches Internationales Servier
      2013   Phase 3   EUCTR2012-001125-27-PT   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
      2013   Phase 3   EUCTR2012-001125-27-GB   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
      2012   -   EUCTR2012-001125-27-GR   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
      2012   -   EUCTR2012-001125-27-DE   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
   Laboratorios Servier S.L.
      2012   -   EUCTR2012-001125-27-ES   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
SOLU MEDROL - 40 MG/ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 40 MG/ML
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy;
SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML
   AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
      2017   Phase 3   EUCTR2017-000845-39-IT   Italy;
Subcutaneous Ustekinumab
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 2   NCT02648581   France;
TA-650
   Mitsubishi Tanabe Pharma Corporation
      2012   Phase 3   NCT01532570   Japan;
Tacrolimus ointment
   Assiut University
      2019   -   NCT05032248   Egypt;
Thalidomide
   Shanghai Traditional Chinese Medicine Hospital
      2021   Phase 0   ChiCTR2000037172   China;
Tocilizumab (TCZ)
   Wenjie Zheng
      2018   Phase 2   NCT03554161   China;
Topical Pentoxifylline Gel (Vehicle +PTX)
   Silk Road Therapies, Inc.
      2020   Phase 2   NCT04186559   United States;
Triamcinolone
   The First Affiliated Hospital of Sun Yat-Sen University
      2021   Phase 0   ChiCTR2100044593   China;
Triamcinolone Acetonide
   Cairo University
      2019   -   NCT03771768   -
Ustekinumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2015   Phase 2   EUCTR2015-002190-37-FR   France;
Veldona,
   Nobel Pharmaceuticals
      2006   Phase 2   NCT00483184   Turkey;
Water
   Tehran University of Medical Sciences
      2010   Phase 4   NCT01306955   Iran, Islamic Republic of;
XOMA 052
   INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
      2012   -   EUCTR2012-001125-27-IT   Brazil;China;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
   Institut de Recherches Internationales Servier
      2013   Phase 3   EUCTR2012-001125-27-PT   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
      2013   Phase 3   EUCTR2012-001125-27-GB   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
      2012   -   EUCTR2012-001125-27-GR   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
      2012   -   EUCTR2012-001125-27-DE   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
   Laboratorios Servier S.L.
      2012   -   EUCTR2012-001125-27-ES   Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2010   Phase 1/Phase 2   NCT01211977   United States;